SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Brain intelligence, fix or adjust creativity thinking, wisdom or improve knowledge learning, tune attitude level or idea development concept, man using wrench adjust gear cogwheels in human brain.
Approvals
Axsome wins first non-antipsychotic FDA approval for Alzheimer’s agitation
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.
May 1, 2026
 · 
2 min read
 · 
Tristan Manalac
Isolated vector design.
Neurodegenerative disease
Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears
Corcept Therapeutics’ amyotrophic lateral sclerosis drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.
May 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Silver Spring, MD, USA 11/10/2020: Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medications, vaccines and food additives for human use.
FDA
FDA taps Szarama as acting CBER director as Prasad’s tumultuous tenure ends
Katherine Szarama, who has served as Prasad’s deputy at the Center for Biologics Evaluation and Research since December, joins a long list of temporary leaders at the Department of Health and Human Services.
May 1, 2026
 · 
2 min read
 · 
Heather McKenzie
Half open secret door new opportunities concept vector illustration, fear of the unknown, step inside the future, what is behind, what is there.
Earnings
Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks
On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic spaces—as the quest continues for a candidate that can top Keytruda.
April 30, 2026
 · 
5 min read
 · 
Gabrielle Masson
Team of businesspeople in paper ship finding the way forward. Manager and team leader concept, vector illustration.
Earnings
Lilly’s weight loss pill reaches brand new patients, even without full-court marketing press
Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for the weight loss pill.
April 30, 2026
 · 
3 min read
 · 
Annalee Armstrong
Emblem design for airlines, airplane tickets, travel agencies. Airplane icon and destination arrow. Flags of the USA and Great Britain. 3D rendering
Huntington’s disease
UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel
UniQure plans to submit AMT-130 to the U.K.’s Medicines and Healthcare products Regulatory Agency in the third quarter of 2026 based on Phase 1/2 data showing a 75% slowing of disease—the same data the FDA has deemed unacceptable for a biologics license application.
April 30, 2026
 · 
2 min read
 · 
Heather McKenzie
Table tennis balls in contrast. Diversity, difference, opposition, exclusion or confrontation concept.
Earnings
BMS positions Cobenfy as safer alternative ahead of pivotal Alzheimer’s psychosis readout
After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers Squibb’s Cobenfy appear set to arrive later this year.
April 30, 2026
 · 
2 min read
 · 
Tristan Manalac
Cost cutting, budget slashing, financial control. Trendy halftone collage. Concept of cost cutting, expense management, and business strategy. Vector illustration
Earnings
Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth
Eli Lilly’s $19.8 billion revenue for the first quarter could have been higher if not for declining prices for key medicines like Zepbound, Mounjaro and Taltz.
April 30, 2026
 · 
2 min read
 · 
Annalee Armstrong
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Schizophrenia
Patient death prompts FDA pause on Newron’s Phase 3 schizophrenia study
The patient death occurred outside the U.S. and was deemed unrelated to Newron Pharmaceuticals’ investigational schizophrenia drug.
April 30, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS